III. 4. The First Week After FMT

In the first week, mild gas, bloating, and changing stool are usually normal signs of colonization — but a few symptoms demand immediate medical help.

The First Week Is the Noisiest – and That Is Expected

The seven days following the first FMT dose are the most symptomatic period of the entire treatment course for most patients. This is not a sign that the treatment is failing. It is the predictable consequence of a rapid, large-scale ecological reorganization taking place in the gut: hundreds of donor microbial species are establishing, competing, fermenting, and signaling simultaneously, and the host's immune and motility systems are responding in real time. Understanding what is happening biologically – and what the expected symptom timeline looks like – is one of the most effective tools for maintaining adherence through this period [51], [50].

The single most common reason patients discontinue FMT prematurely is misinterpretation of normal early-phase symptoms as signs of treatment failure or serious adverse events. A 2022 analysis of FMT adherence found that patients who received structured written guidance about expected first-week symptoms had significantly higher treatment completion rates than those who did not, independent of clinical response [51]. This chapter provides that guidance in detail.

What Is Normal in the First Week

Stool changes: the most immediate and expected response. Changes in stool frequency, consistency, and appearance begin within 12–48 hours of the first FMT dose in most patients and represent the most direct observable marker of ecological activity. Looser stools or diarrhea in the first 2–5 days are normal and reflect increased fermentation activity, shifts in bile acid metabolism, and changes in colonic water reabsorption as the new microbial community establishes. Stool color may temporarily shift toward darker brown or greenish tones, reflecting altered bile acid processing and changes in transit time. Increased stool frequency – up to 4–6 per day in the first 48–72 hours after colonoscopic FMT – is within the expected range and does not warrant treatment or intervention. By days 4–7, frequency and consistency typically begin to normalize toward a more stable pattern, though full normalization may take 2–4 weeks [7], [35].

Flatulence and bloating: the fermentation signal. Increased gas production and abdominal bloating are among the most consistent early-phase symptoms, reported by 40–70% of patients in the first week post-FMT across multiple clinical series [50], [35]. These symptoms reflect active fermentation by the incoming donor community as it encounters the available dietary substrates in the colon. The donor community arrives with a full complement of fermentative enzymes and may initially produce more gas than the recipient's previous microbiome, particularly if the recipient has been on a low-fiber or antibiotic-depleted diet prior to FMT. Bloating is typically most pronounced in the first 2–4 days and diminishes progressively as the community stabilizes. It is uncomfortable but not dangerous, and does not require dietary intervention beyond the low-fermentation guidance in Chapter III.1 Version B. Simethicone (activated dimethicone) can be used for symptom relief if gas-related discomfort is significant; this does not interfere with engraftment [50].

Mild abdominal cramping: peristaltic (wave-like muscle contractions that propel gut contents forward) reorganization. Mild to moderate cramping – described by patients as waves of discomfort that resolve spontaneously and are often relieved by passing gas or stool – is a normal first-week finding. It reflects changes in intestinal motility driven by altered microbial metabolite signaling, particularly shifts in SCFA composition and secondary bile acid profiles that modulate the enteric nervous system [39]. Cramping that resolves with defecation or flatulence, that is not progressively worsening, and that is not associated with fever or rectal bleeding is within the expected range. Antispasmodic agents (e.g., hyoscine butylbromide) may be used for symptom relief if cramping is significantly distressing; this does not affect engraftment.

Fatigue and temporary malaise: the immune response window. A proportion of patients – estimated at 20–40% across studies – report mild fatigue, general malaise, or low energy in the first 3–5 days after FMT [50], [35]. This likely reflects a transient systemic immune response to the new microbial community: the mucosal immune system is sampling the incoming donor taxa and generating an initial inflammatory and regulatory response. In most patients this is mild and self-limiting; it resolves as immune tolerance develops and is not associated with adverse outcomes. Resting more than usual, reducing strenuous physical activity during this window, and maintaining adequate hydration and nutrition are the appropriate responses. Persistent fatigue beyond day 5, or fatigue accompanied by fever or other systemic symptoms, requires clinical evaluation.

Appetite changes: transient and self-limiting. Reduced appetite or mild nausea in the first 1–3 days after FMT is common, particularly after colonoscopic delivery. It reflects the combined effects of bowel preparation, the procedural experience, altered gut motility, and early fermentative gas production. Patients should maintain fluid intake (minimum 1.5–2 L/day) and eat small, easily digestible meals even if appetite is reduced. Full appetite typically returns within 2–4 days. Maintaining nutritional intake during this period is important: the incoming donor community requires dietary substrate to establish, and prolonged fasting or severe appetite suppression in the first week can impair engraftment [52].

Normal Responses vs. Warning Signs – Day-by-Day Reference

Table 6 – First-week symptom reference guide # The 'normal' column describes expected responses that do not require clinical intervention. The 'warning sign' column describes findings that require prompt clinical contact regardless of time of day. When in doubt, contact your clinical team.

A Day-by-Day Overview of the First Week

Days 1–2: Peak ecological turbulence. The first 48 hours after induction-phase FMT are typically the most symptomatic. For colonoscopic FMT patients, residual effects of the bowel preparation – including increased stool frequency and fluid loss – overlap with the initial fermentation response from the donor community. Capsule FMT patients typically experience a more gradual onset. The priority in this period is hydration (minimum 2 L/day), rest, and maintaining light dietary intake. Begin your Food and Symptom Diary entries from day 1 if you have not already done so.

Days 3–4: Early stabilization. Stool frequency typically begins to decrease, and consistency begins to firm up. Bloating often remains significant but is usually less acute. Energy levels begin to return. Appetite typically improves. This is a critical monitoring window: patients who show no improvement in stool frequency or consistency by day 4, or who develop new symptoms in this period, should contact their clinical team.

Days 5–7: Ecological consolidation begins. Most patients report meaningful improvement in stool consistency and a reduction in gas and bloating by days 5–7. This represents the beginning of ecological stabilization: the donor community is establishing dominant positions in the colonic niche landscape, SCFA production is normalizing, and bile acid profiles are shifting toward a pattern more supportive of colonization resistance. Some patients report improvements in energy, mood, or sleep during this window, reflecting early changes in gut-brain axis signaling [39], [53]. This is also the window in which the Phase 0 compatibility signal becomes interpretable: the clinical team will review your diary at the end of the first 8-day cycle to assess the preparation response.

What if symptoms are not improving by day 7? A minority of patients experience a prolonged first-week symptomatic period beyond day 7. This does not necessarily indicate treatment failure. In inflammatory bowel disease in particular, the initial FMT-induced ecological disruption may extend the symptomatic period to 10–14 days before net improvement appears [35], [31]. However, any worsening beyond baseline – rather than unchanged or gradually improving symptoms – warrants clinical review. The clinical team uses this assessment to distinguish expected prolonged response from adverse events or compatibility issues requiring protocol modification.

Reading the Compatibility Signal During Phase 0

Patients in the compatibility assessment phase (Phase 0) are undergoing a structured clinical observation rather than full induction. The symptom experience during each 8-day cycle is used to generate a compatibility profile for each tested donor preparation. Understanding how the clinical team interprets this signal helps patients engage more actively with their diary documentation.

Positive compatibility signal. Defined as: partial or complete improvement in at least one target symptom (e.g., stool consistency, bloating, pain), absence of new adverse symptoms, and no systemic response (no fever, no skin reactions). A positive signal does not require dramatic improvement – even stabilization or mild improvement counts as a favorable response at the low doses used in Phase 0. A positive signal confirms that the selected preparation can proceed to induction.

Neutral signal. Defined as: no meaningful change in target symptoms in either direction, no adverse response. A neutral signal may reflect insufficient dose for a detectable response at Phase 0 levels, donor-preparation mismatch, or a host microbiome that is currently too resistant to ecological perturbation at low doses. The clinical team will assess whether to proceed with the same preparation at induction dose or to test an alternative preparation in the next cycle.

Adverse signal. Defined as: new or significantly worsened symptoms that are temporally associated with the preparation administration and not explained by dietary or other confounding factors. An adverse signal prompts immediate preparation switch and clinical review. It does not mean FMT will not work – it means the specific preparation tested is not the right match, and the iterative selection process moves to the next candidate preparation. This is precisely why Phase 0 exists.

Microbiota Effects

• In the 24–72 hours following colonoscopic FMT, microbiome sequencing studies show rapid and large-scale shifts in community composition: donor taxa begin to appear in recipient stool within the first 24 hours, and in successful engraftment, donor taxa represent the majority of detectable sequences within 48–72 hours [7], [34].
• Early post-FMT diarrhea and loose stools reflect a combination of altered colonic water reabsorption – as the new microbial community reorganizes fluid and electrolyte transport signaling – and transiently increased fermentation load; the net effect on stool consistency typically normalizes within 3–7 days as fermentation reaches ecological equilibrium [7], [35].
• SCFA profiles in stool shift substantially in the first week post-FMT, with butyrate concentrations rising progressively as butyrate-producing donor taxa (Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale) establish in the recipient colon; this SCFA shift is correlated with improvements in mucosal barrier function and reductions in inflammatory signaling [39], [54].
• Secondary bile acid metabolism is restored within days of successful FMT in CDI patients, with recipient stool showing increasing concentrations of secondary bile acids (deoxycholic acid, lithocholic acid) that inhibit C. difficile germination and spore formation; this bile acid shift is one of the primary mechanisms of rapid CDI cure [7].
• Mucosal innate immune activation – reflected in fecal calprotectin (a stool protein marker of intestinal inflammation) (a stool-measurable protein that indicates intestinal inflammation) levels – typically shows an initial transient elevation in the first 3–5 days post-FMT, followed by a progressive decline over weeks 2–6 as mucosal immune tolerance to the donor community develops; an initial calprotectin rise is therefore expected and does not indicate adverse mucosal injury [31], [54].
• Gut-brain axis signaling changes are detectable within the first week in some patients: early shifts in tryptophan metabolism toward serotonin precursor production, and normalization of GABA precursor availability, may contribute to the mood and energy improvements reported by a subset of patients in days 5–7 [53].
• Bacteriophage communities transferred during FMT begin reshaping the recipient's bacterial community composition within the first 48–72 hours through selective bacterial predation; phage engraftment is typically more durable than bacterial engraftment in some patients, with donor phage detectable in recipient stool at 12 months post-FMT in up to 40% of cases [30].

Patient Guidance

• From the day of your first FMT dose, carry your Food and Symptom Diary with you or have it immediately accessible. Record every day: stool frequency and Bristol scale score, abdominal symptoms rated 0–10, energy level rated 0–10, what you ate and drank, any medications taken, and any unusual symptoms.
• Prioritize hydration in the first week: aim for a minimum of 2 liters of water or non-caffeinated fluids per day. Loose stools and increased fermentation activity increase fluid loss; inadequate hydration can worsen fatigue, concentrate urine, and contribute to post-FMT headaches.
• Eat regular, small meals in the first 3 days even if your appetite is reduced. Choose easily digestible foods with moderate fiber content: oat porridge, cooked vegetables, ripe banana, white rice with cooled potato, steamed fish or chicken. Avoid raw brassicas, dried legumes, raw onion and garlic, and high-fat foods in the first 5 days. Follow the Version B dietary guidance from Chapter III.1.
• Reduce physical exercise intensity in the first 3–5 days. Light walking is beneficial and supports intestinal motility; high-intensity training, heavy lifting, or endurance exercise should be avoided until stool pattern stabilizes. Vigorous exercise during the peak ecological turbulence period increases intestinal permeability and may adversely affect engraftment [52].
• Do not self-medicate with anti-diarrheal agents (loperamide, codeine phosphate) without clinical guidance. These agents reduce intestinal motility and can impair the distribution and ecological establishment of the donor community in the first week. If diarrhea is severely distressing, contact your clinical team before taking any anti-motility medication.
• Simethicone (activated dimethicone) is safe to use for gas and bloating relief and does not interfere with engraftment. Standard over-the-counter doses (40–125 mg after meals and at bedtime) may be taken as needed. Antispasmodics (e.g., hyoscine butylbromide) may be taken for cramping relief if the clinical team has not contraindicated them.
• Do not interpret the first week’s symptoms as the final outcome of your treatment. The first 7 days represent ecological turbulence, not the endpoint. The therapeutic benefit of FMT typically emerges from weeks 2 onward as the new community consolidates. Premature discontinuation based on first-week symptoms is one of the most common and most avoidable reasons for treatment failure.
• If your underlying condition appears to worsen in the first week, do not panic and do not immediately attribute this to treatment failure. Initial worsening is documented in 20–35% of IBD patients in the first 1–2 weeks of FMT and is not predictive of final outcome [35], [31]. Document the worsening in your diary, contact your clinical team for assessment, and continue the protocol unless specifically directed otherwise.
• Refer to the warning signs listed in Table 1 of this chapter every day for the first week. If you experience any item from the warning sign column, contact your clinical team immediately. Do not wait for a scheduled appointment; do not attempt to self-manage warning signs.
• At the end of day 7 (or at the scheduled first follow-up), have your diary data ready for review by your clinical team. This review is the primary clinical tool for assessing Phase 0 compatibility and for making decisions about the next cycle. The quality of your diary documentation directly determines the quality of the clinical decision.

References

[7] van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013. Link

Open-label RCT in patients with recurrent C. difficile infection comparing duodenal donor faeces infusion (after short vancomycin + bowel lavage) with standard 14-day vancomycin, with or without bowel lavage. The primary endpoint was diarrhoea resolution without relapse at 10 weeks. The trial was stopped early at interim analysis: 13/16 patients (81\%) in the FMT arm achieved resolution after a single infusion, substantially exceeding both vancomycin arms. Establishes FMT as superior to antibiotic monotherapy for recurrent CDI and provides the landmark evidence base for FMT clinical translation.

[30] Zuo T, Wong SH, Lam K et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut. 2018. Link

Investigation of enteric virome alterations in 24 CDI subjects and 20 healthy controls using ultra-deep metagenomic sequencing of virus-like particles plus 16S rRNA bacterial profiling. Nine CDI patients treated with FMT and five treated with vancomycin were longitudinally assessed for virome and bacteriome changes in relation to treatment response. The data link viral transfer during FMT — particularly bacteriophages — with clinical resolution of CDI, suggesting that phage transfer contributes to the therapeutic effect beyond bacterial engraftment alone.

[31] Moayyedi P, Surette MG, Kim PT et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015. Link

Placebo-controlled randomized trial in patients with active ulcerative colitis without infectious diarrhoea. Participants were randomized to FMT (50 mL enema from healthy anonymous donors, n=38) or placebo water enema (n=37) once weekly for 6 weeks; patients, clinicians, and investigators were blinded. The trial assessed safety and efficacy of FMT for inducing remission in UC, demonstrating that FMT can produce clinical and endoscopic improvement beyond placebo in a subset of patients. Findings support FMT as a microbiota-modulating option in active UC while highlighting variable individual response.

[34] Smillie CS, Sauk J, Gevers D et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe. 2018. Link

Strain-level analysis of FMT for recurrent Clostridium difficile infection introducing Strain Finder, a method for inferring strain genotypes and tracking engraftment longitudinally. A statistical model predicted species-level engraftment largely from donor abundance and pre-FMT recipient phylogeny. Donor strains within a species engrafted in an all-or-nothing manner, and previously undetected strains frequently colonized recipients. The work defines the determinants of bacterial engraftment in human FMT and provides a framework for predicting graft outcomes.

[35] Paramsothy S, Kamm MA, Kaakoush NO et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017. Link

Paramsothy and colleagues report the FOCUS trial, a landmark Lancet 2017 randomised placebo-controlled study of multidonor intensive fecal microbiota transplantation (FMT) in active ulcerative colitis. Eighty-one adults with mild-to-moderate active UC received either pooled-donor FMT or placebo enemas, with an induction colonoscopic infusion followed by enemas five days per week for eight weeks. The primary endpoint of steroid-free clinical remission with endoscopic remission or response at week 8 was achieved in 27% of FMT versus 8% of placebo recipients (p=0.021). Microbial diversity increased in responders, with specific Fusobacterium decreases and Eubacterium and Roseburia increases. The trial established multidonor, intensive-dose FMT as a credible therapeutic strategy in UC.

[39] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link

Mechanistic review of short-chain fatty acids (SCFAs) — a major class of bacterial metabolites derived from dietary fibre fermentation — as central mediators between diet, gut microbiota, and host physiology. SCFAs activate G-protein-coupled receptors, inhibit histone deacetylases, and serve as energy substrates, thereby influencing metabolic, immune, and epigenetic processes. The authors synthesize evidence implicating SCFA-mediated signalling in both health maintenance and disease pathogenesis. Provides the conceptual backbone for fibre-based and microbiome-directed therapeutic strategies.

[50] Marcella C, Cui B, Kelly CR, Ianiro G, Cammarota G, Zhang F. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther. 2000. Link

Systematic review of FMT safety summarizing adverse events (AEs) over 20 years from 129 studies including 4,241 patients and 5,688 FMT courses (search of EMBASE, MEDLINE, Cochrane, CNKI, Wanfang from 2000 to 2020). AEs were classified as delivery-related or microbiota-related. The review provides the largest aggregate FMT safety dataset to date and supports the overall favourable safety profile of FMT for recurrent CDI, while flagging that complications may be under-reported in the literature.

[51] Hourigan SK, Oliva-Hemker M. Fecal Microbiota Transplantation in Children: A Brief Review. Pediatr Res. 2016. Link

Review of FMT in paediatric populations for CDI and IBD, highlighting that children's evolving microbiome differs from the relatively stable adult microbiome and may require adapted protocols. The authors summarize published paediatric experience and discuss special considerations including dosing, donor screening, route of administration, and ethical aspects. Provides a clinical framework for paediatric FMT decisions in CDI and IBD where data remain limited.

[52] Cook MD, Allen JM, Pence BD et al. Exercise and gut immune function: evidence of alterations in colon immune cell homeostasis and microbiome characteristics with exercise training. Immunol Cell Biol. 2016. Link

Review of habitual physical activity as an anti-inflammatory factor with effects extending to the gut microbiome. Exercise may attenuate inflammatory disease susceptibility partly through favourable shifts in microbiome composition and improved gut immune function. The authors integrate emerging animal and human data linking moderate exercise with increased microbial diversity and butyrate-producing taxa. The paper supports physical activity as a non-pharmacological modulator of the gut microbiota–immune axis.

[53] Cryan JF, O'Riordan KJ, Cowan CSM et al. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019. Link

Review of free fatty acids (FFAs) — including dietary long- and medium-chain fatty acids and microbially produced short-chain fatty acids (SCFAs) — as ligands for free fatty acid receptors (FFARs), a group of G protein-coupled receptors linking metabolism and immunity. FFARs regulate inflammation, peptide hormone secretion, and host energy balance. The authors summarize FFAR pharmacology and its translational potential as a target for metabolic and inflammatory disease.

[54] Sokol H, Landman C, Seksik P et al. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. Microbiome. 2020. Link

Randomized, single-blind, sham-controlled pilot trial of FMT in adults with colonic or ileo-colonic Crohn's disease in steroid-induced clinical remission. Patients were randomized at remission to receive FMT or sham transplantation during colonoscopy; corticosteroids were tapered and follow-up colonoscopy performed at week 6. The trial provides the first randomized data on FMT for maintaining remission in CD, with modest signals supporting microbial engraftment as a candidate driver of clinical response and informing larger confirmatory studies.